An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Inclusion criteria

• Healthy Japanese male or female subjects by completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
• BMI between 18.5 and 25.0 kg∙m-2, both inclusive.
• Fasting Plasma Glucose ≤ 5.6 mmol/L (100 mg/dL).
• Signed and dated informed consent obtained before any trial-related activities.

Exclusion criteria

• Known or suspected hypersensitivity to trial product(s) or related products.
• Receipt of any investigational medicinal product within 3 months before randomisation in this trial.
• Any history or presence of a life threatening disease (i.e. cancer except basal cell skin cancer or squamous cell skin cancer), or of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic (including type 1 and type 2 diabetes mellitus, haematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the investigator.
• History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.